Heterogeneity in the multiple myeloma tumor clone

Leukemia and Lymphoma

Volumn 45, Issue 5, 2004, Pages 857-871

  Guikema, Jeroen E J ^a,b   Hovenga, Sjoerd ^b   Vellenga, Edo ^b   Bos, Nicolaas A ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chromosomal abnormalities; Clonotypic B cell; Heterogeneity; Immunophenotype; Multiple myeloma

Indexed keywords

B LYMPHOCYTE; BLOOD; BONE MARROW; CELL CLONE; CELL HETEROGENEITY; CELL MATURATION; CELL STRUCTURE; CELL TYPE; DISEASE COURSE; GENETIC DISORDER; HUMAN; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

B-LYMPHOCYTES; CLONE CELLS; HUMANS; IMMUNOGLOBULIN SWITCH REGION; IMMUNOPHENOTYPING; MULTIPLE MYELOMA;

EID: 1842555117     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190310001593201     Document Type: Review

References (140)

1. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., et al. (1996) "A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome", New England Journal of Medicine, 335, 91-97.
2. Medina, F., Segundo, C., Campos-Caro, A., Gonzalez-Garcia, I. and Brieva, J.A. (2002) "THe heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression", Blood, 99, 2154-2161.
3. Kurabayashi, H., Kubota, K., Tamura, J., Naruse, T., Murakami, H. and Tsuchiya, J. (1998) "CLinical analysis of the prognostic value of ultrastructural abnormalities of plasma cells in patients with multiple myeloma", Ultrastructural Pathology, 22, 439-442.
4. Bartl, R., Frisch, B., Burkhardt, R., Fateh-Moghadam, A., Mahl, G., Gierster, P., et al. (1982) "BOne marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging", British Journal of Haematology, 51, 361-375.
5. Fritz, E., Ludwig, H. and Kundi, M. (1984) "PRognostic relevance of cellular morphology in multiple myeloma", Blood, 63, 1072-1079.
6. Greipp, P.R., Raymond, N.M., Kyle, R.A. and O'Fallon, W.M. (1985) "MUStiple myeloma: significance of plasmablastic subtype in morphological classification", Blood, 65, 305-310.
7. Carter, A., Hocherman, I., Linn, S., Cohen, Y. and Tatarsky, I. (1987) "PRognostic significance of plasma cell morphology in multiple myeloma", Cancer, 60, 1060-1065.
8. Pasqualetti, P., Colantonio, D., Collacciani, A., Casale, R. and Natali, G. (1991) "CLassification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications", Panminerva Medica, 33, 93-110.
9. Greipp, P.R., Leong, T., Bennett, J.M., Gaillard, J.P., Klein, B., Stewart, J.A., et al. (1998) "PLasmablastic morphology - an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group", Blood, 91, 2501-2507.
10. Rajkumar, S.V., Fonseca, R., Lacy, M.Q., Witzig, T.E., Therneau, T.M., Kyle, R.A., et al. (1999) "PLasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma", Journal of Clinical Oncology, 17, 1551-1557.
11. Goasguen, J.E., Zandecki, M., Mathiot, C., Scheiff, J.M., Bizet, M., Ly-Sunnaram, B., et al. (1999) "MAture plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology", Leukemia Research, 23, 1133-1140.
12. Bakkus, M.H., Heirman, C., Van, R.I., Van Camp, B. and Thielemans, K. (1992) "EVidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation", Blood, 80, 2326-2335.
13. Vescio, R.A., Cao, J., Hong, C.H., Lee, J.C., Wu, C.H., Der, D.M., et al. (1995) "MYeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity", Journal of Immunology, 155, 2487-2497.
14. Alexanian, R., Barlogie, B. and Dixon, D. (1990) "REnal failure in multiple myeloma. Pathogenesis and prognostic implications", Archives of Internal Medicine, 150, 1693-1695.
15. Irish, A.B., Winearls, C.G. and Littlewood, T. (1997) "PResentation and survival of patients with severe renal failure and myeloma", QJM, 90, 773-780.
16. MacLennan, I.C. (1992) "IN which cells does neoplastic transformation occur in myelomatosis?", Current Topics in Microbiology and Immunology, 182, 209-214.
17. Avet-Loiseau, H., Garand, R., Lode, L., Harousseau, J.L. and Bataille, R. (2003) "TRanslocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants", Blood, 101, 1570-1571.
18. Juge-Morineau, N., Heirman, C., Bakkus, M., Van Camp, B., Malfait, R., Harousseau, J.L., et al. (1997) "IMmunoglobulins D and M multiple myeloma variants are heavily mutated", Clinical Cancer Research, 3, 2501-2506.
19. Sahota, S.S., Garand, R., Mahroof, R., Smith, A., Juge-Morineau, N., Stevenson, F.K., et al. (1999) "V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events", Blood, 94, 1070-1076.
20. Arpin, C., de Bouteiller, O., Razanajaona, D., Fugier-Vivier, I., Briere, F., Banchereau, J., et al. (1998) "THe normal counterpart of IgD myeloma cells in germinal center displays extensively mutated IgVH gene, Cmu-Cdelta switch, and lambda light chain expression", Journal of Experimental Medicine, 187, 1169-1178.
21. Fine, J.M., Rivat, C., Lambin, P. and Ropartz, C. (1974) "MOnoclonal IgD. A comparative study of 60 sera with IgD " M" component", Biomedicine, 21, 119-125.
22. Fibbe, W.E. and Jansen, J. (1984) "PRognostic factors in IgD myeloma: A study of 21 cases", Scandinavian Journal of Haematology, 33, 471 -475.
23. van der Burg, M., Bende, R.J., Aarts, W.M., Langerak, A.W., van Dongen, J.J. and van Noesel, C.J. (2002) "BIased Iglambda expression in hypermutated IgD multiple myelomas does not result from receptor revision", Leukemia, 16, 1358-1361.
24. Durie, B.G. and Salmon, S.E. (1975) "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival", Cancer, 36, 842-854.
25. Zent, C.S., Wilson, C.S., Tricot, G., Jagannath, S., Siegel, D., Desikan, K.R., et al. (1998) "OLigoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation", Blood, 91, 3518-3523.
26. Guikema, J.E., Vellenga, E., Veeneman, J.M., Hovenga, S., Bakkus, M.H., Klip, H., et al. (1999) "MUltiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation", British Journal of Haematology, 104, 748-754.
27. Hovenga, S., de Wolf, J.T., Guikema, J.E., Klip, H., Smit, J.W., Smit Sibinga, C.T., et al. (2000) "AUtologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: A high incidence of oligoclonal serum Igs post transplantation", Bone Marrow Transplantation, 25, 723-728.
28. Corradini, P., Boccadoro, M., Voena, C. and Pileri, A. (1993) "EVidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas", Journal of Experimental Medicine, 178, 1091-1096.
29. Billadeau, D., Ahmann, G., Greipp, P. and Van Ness, B. (1993) "THe bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell", Journal of Experimental Medicine, 178, 1023-1031.
30. Sahota, S.S., Garand, R., Mahroof, R., Smith, A., Juge-Morineau, N., Stevenson, F.K., et al. (1999) "V(H) gene analysis of IgM-secreting myeloma indicates an origin from a memory cell undergoing isotype switch events", Blood, 94, 1070-1076.
31. Reiman, T., Seeberger, K., Taylor, B.J., Szczepek, A.J., Hanson, J., Mant, M.J., et al. (2001) "PErsistent preswitch clonotypic myeloma cells correlate with decreased survival: Evidence for isotype switching within the myeloma clone", Blood, 98, 2791-2799.
32. Guikema, J.E., Vellenga, E., Bakkus, M.H. and Bos, N.A. (2002) "MYeloma clonotypic B cells are hampered in their ability to undergo B- cell differentiation in vitro", British Journal of Haematology, 119, 54-61.
33. Bakkus, M.H., Asosingh, K., Vanderkerken, K., Thielemans, K., Hagemeijer, A., De Raeve, H., et al. (2001) "MYeloma isotype-switch variants in the murine 5T myeloma model: Evidence that myeloma IgM and IgA expressing subclones can originate from the IgG expressing tumour", Leukemia, 15, 1127-1132.
34. Bloem, A.C., Chand, M.A., Van Camp, B., Bast, E.J. and Ballieux, R.E. (1988) "PHenotypical and functional characterization of the idiotype-positive blood B cells in multiple myeloma", Scandinavian Journal of Immunology, 28, 791-799.
35. Kubagawa, H., Vogler, L.B., Capra, J.D., Conrad, ME., Lawton, A.R. and Cooper, M.D. (1979) "STudies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation", Journal of Experimental Medicine, 150, 792-807.
36. Osterborg, A., Steinitz, M., Lewin, N., Bergenbrant, S., Holm, G., Lefvert, A.K., et al. (1991) "EStablishment of idiotype bearing B-lymphocyte clones from a patient with monoclonal gammopathy", Blood, 78, 2642-2649.
37. Pilarski, L.M. and Belch, A.R. (1994) "CIrculating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma", Blood, 83, 724-736.
38. Pilarski, L.M., Szczepek, A.J. and Belch, A.R. (1997) "DEficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma", Blood, 90, 3751-3759.
39. Szczepek, A.J., Seeberger, K., Wizniak, J., Mant, M.J., Belch, A.R. and Pilarski, L.M. (1998) "A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase- polymerase chain reaction", Blood, 92, 2844-2855.
40. Chen, B.J. and Epstein, J. (1905) "CIrculating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells", Blood, 1996 Mar 1;87(5):1972-6. :1972-6., 6.
41. Szczepek, A.J., Bergsagel, P.L., Axelsson, L., Brown, C.B., Belch, A.R. and Pilarski, L.M. (1997) "CD34 + cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements", Blood, 89, 1824-1833.
42. Pilarski, L.M., Giannakopoulos, N.V., Szczepek, A.J., Masellis, A.M., Mant, M.J. and Belch, A.R. (2000) "IN multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease", Clinical Cancer Research, 6, 585-596.
43. Szczepek, A.J., Belch, A.R. and Pilarski, L.M. (2001) "EXpression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: Potential for autocrine and paracrine networks", Experimental Hematology, 29, 1076-1081.
44. Willems, P., Croockewit, A., Raymakers, R., Holdrinet, R., van Der, B.G., Huys, E., et al. (1996) "CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34 + myeloma cells", British Journal of Haematology, 93, 613-622.
45. Voena, C., Locatelli, G., Castellino, C., Omede, P., Ladetto, M., Zappone, E., et al. (2002) "QUalitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34 + cells with small- and large-scale Miltenyi cell sorting system", British Journal of Haematology, 117, 642-645.
46. Rasmussen, T., Jensen, L., Honore, L., Andersen, H. and Johnsen, H.E. (1999) "CIrculating clonal cells in multiple myeloma do not express CD34 mRNA, as measured by single-cell and real-time RT-PCR assays", British Journal of Haematology, 107, 818-824.
47. Kay, N.E., Leong, T., Kyle, R.A., Greipp, P., Billadeau, D., Van Ness, B., et al. (1997) "CIrculating blood B cells in multiple myeloma: Analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial", Blood, 90, 340-345.
48. Kay, N.E., Leong, T.L., Bone, N., Vesole, D.H., Greipp, P.R., Van Ness, B., et al. (2001) "BLood levels of immune cells predict survival in myeloma patients: Results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients", Blood, 98, 23-28.
49. Davies, F.E., Rawstron, A.C., Pratt, G., O'Connor, S., Su'ut, L., Blythe, D., et al. (1999) "FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells", British Journal of Haematology, 106, 40-46.
50. Zandecki, M., Bernardi, F., Genevieve, F., Lai, J.L., Preudhomme, C., Flactif, M., et al. (1997) "INvolvement of peripheral blood cells in multiple myeloma: Chromosome changes are the rule within circulating plasma cells but not within B lymphocytes", Leukemia, 11, 1034-1039.
51. Zojer, N., Schuster-Kolbe, J., Assmann, I., Ackermann, J., Strasser, K., Hubl, W., et al. (2002) "CHromosomal aberrations are shared by malignant plasma cells and a small fraction of circulating CD19 + cells in patients with myeloma and monoclonal gammopathy of undetermined significance", British Journal of Haematology, 117, 852-859.
52. Bergsagel, P.L., Smith, A.M., Szczepek, A., Mant, M.J., Belch, A.R. and Pilarski, L.M. (1995) "IN multiple myeloma, clonotypic B lymphocytes are detectable among CD19 + peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain", Blood, 85, 436-447.
53. Kiel, K., Cremer, F.W., Rottenburger, C., Kallmeyer, C., Ehrbrecht, E., Atzberger, A., et al. (1999) "ANalysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation", Bone Marrow Transplantation, 23, 1019-1027.
54. Rottenburger, C., Kiel, K., Bosing, T., Cremer, F.W., Moldenhauer, G., Ho, A.D., et al. (1999) "CLonotypic CD20 + and CD19 + B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation", British Journal of Haematology, 106, 545-552.
55. Rasmussen, T. (2001) "THe presence of circulating clonal CD19 + cells in multiple myeloma", Leukemia and Lymphoma, 42, 1359-1366.
56. Schiller, G., Vescio, R., Freytes, C., Spitzer, G., Sahebi, F., Lee, M., et al. (1995) "TRansplantation of CD34 + peripheral blood progenitor cells after high- dose chemotherapy for patients with advanced multiple myeloma", Blood, 86, 390-397.
57. Mitterer, M., Lanthaler, A.J., Schnabel, B., Svaldi, M., Oduncu, F., Coser, P., et al. (2001) "PEripheral blood monoclonal B-cells predict the event free survival in multiple myeloma", Leukemia and Lymphoma, 41, 387-395.
58. Pilarski, L.M., Hipperson, G., Seeberger, K., Pruski, E., Coupland, R.W. and Belch, A.R. (2000) "MYeloma progenitors in the blood of patients with aggressive or minimal disease: Engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice", Blood, 95, 1056-1065.
59. Wijdenes, J., Vooijs, W.C., Clement, C., Post, J., Morard, F., Vita, N., et al. (1996) "A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1", British Journal of Haematology, 94, 318-323.
60. Dhodapkar, M.V., Abe, E., Theus, A., Lacy, M., Langford, J.K., Barlogie, B., et al. (1998) "SYndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation", Blood, 91, 2679-2688.
61. Seidel, C., Sundan, A., Hjorth, M., Turesson, I., Dahl, I.M., Abildgaard,AN., et al. (2000) "SErum syndecan-1: a new independent prognostic marker in multiple myeloma", Blood, 95, 388-392.
62. Schneider, U., van Lessen, A., Huhn, D. and Serke, S. (1997) "TWo subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen", British Journal of Haematology, 97, 56-64.
63. Mahmoud, M.S., Ishikawa, H., Fujii, R. and Kawano, M.M. (1998) "INduction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6", Blood, 92, 3887-3897.
64. Ishikawa, H., Mahmoud, M.S., Fujii, R., Abroun, S. and Kawano, M.M. (2000) "PRoliferation of immature myeloma cells by interieukin-6 is associated with CD45 expression in human multiple myeloma", Leukemia and Lymphoma, 39, 51-55.
65. Rawstron, A.C., Fenton, J.A., Ashcroft, J., English, A., Jones, R.A., Richards, S.J., et al. (2000) "THe interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells", Blood, 96, 3880-3886.
66. Asosingh, K., De Raeve, H., Croucher, P., Goes, E., Van, R.I., Van Camp, B., et al. (2001) "IN vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45 + ) 5T multiple myeloma cells", Experimental Hematology, 29, 77-84.
67. Caligaris-Cappio, F., Bergui, L., Tesio, L., Pizzolo, G., Malavasi, F., Chilosi, M., et al. (1985) "IDentification of malignant plasma cell precursors in the bone marrow of multiple myeloma", Journal of Clinical Investigation, 76, 1243-1251.
68. Cao, J., Vescio, R.A., Rettig, M.B., Hong, C.H., Kim, A., Lee, J.C., et al. (1995) "A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers", Leukemia, 9, 1948-1953.
69. Van Camp, B., Durie, B.G., Spier, C., De Waele, M., Van, R.I., Vela, E., et al. (1990) "PLasma cells in multiple myeloma express a natural killer cell- associated antigen: CD56 (NKH-1; Leu-19 ", Blood, 76, 377-382.
70. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K., Naito, K., et al. (2002) "CLinicopathological and prognostic characteristics of CD56-negative multiple myeloma", British Journal of Haematology, 117, 882-885.
71. Mathew, P., Ahmann, G.J., Witzig, T.E., Roche, P.C., Kyle, R.A. and Greipp, P.R. (1995) "CLinicopathological correlates of CD56 expression in multiple myeloma: A unique entity?", British Journal of Haematology, 90, 459-461.
72. Rawstron, A., Barrans, S., Blythe, D., Davies, F., English, A., Pratt, G., et al. (1999) "DIstribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression", British Journal of Haematology, 104, 138-143.
73. Pellat-Deceunynck, C., Barille, S., Puthier, D., Rapp, M.J., Harousseau, J.L., Bataille, R., et al. (1995) "ADhesion molecules on human myeloma cells: Significant changes in expression related to malignancy, tumor spreading, and immortalization", Cancer Research, 55, 3647-3653.
74. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., et al. (1998) "THe absence of CD56 (NCAM on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma", Leukemia, 12, 1977-1982.
75. Dahl, I.M., Rasmussen, T., Kauric, G. and Husebekk, A. (2002) "DIfferential expression of CD56 and CD44 in the evolution of extramedullary myeloma", British Journal of Haematology, 116, 273-277.
76. Harada, H., Kawano, M.M., Huang, N., Harada, Y., Iwato, K., Tanabe, O., et al. (1993) "PHenotypic difference of normal plasma cells from mature myeloma cells", Blood, 81, 2658-2663.
77. Mahmoud, M.S., Fujii, R., Ishikawa, H. and Kawano, M.M. (1999) "ENforced CD19 expression leads to growth inhibition and reduced tumorigenicity", Blood, 94, 3551-3558.
78. San Miguel, J.F., Almeida, J., Mateo, G., Blade, J., Lopez-Berges, C., Caballero, D., et al. (2002) "IMmunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome", Blood, 99, 1853-1856.
79. Rawstron, A.C., Davies, F.E., DasGupta, R., Ashcroft, A.J., Patmore, R., Drayson, M.T., et al. (2002) "FLow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation", Blood, 100, 3095-3100.
80. Sahara, N., Ihara, M., Ono, T., Tamashima, S., Matsui, H., Takeshita, A. and Ohno, R. (2000) "MUltiple myeloma expressing CD19( + )CD56( - ) phenotype", American Journal of Hematology, 64, 311-313.
81. Eisterer, W., Bechter, O., Hilbe, W., van Driel, M., Lokhorst, H.M., Thaler, J., et al. (2001) "CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma", Leukemia Research, 25, 1051-1057.
82. Stauder, R., van Driel, M., Schwarzler, C., Thaler, J., Lokhorst, H.M., Kreuser, E.D., et al. (1996) "DIfferent CD44 splicing patterns define prognostic subgroups in multiple myeloma", Blood, 88, 3101-3108.
83. van Driel, M., Gunthert, U., Stauder, R., Joling, P., Lokhorst, H.M. and Bloem, A.C. (1998) "CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease", Leukemia, 12, 1821-1828.
84. van Driel, M., Gunthert, U., van Kessel, A.C., Joling, P., Stauder, R., Lokhorst, H.M., et al. (2002) "CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells", Leukemia, 16, 135-143.
85. San Miguel, J.F., Gonzalez, M., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., et al. (1991) "IMmunophenotypic heterogeneity of multiple myeloma: Influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies", British Journal of Haematology, 77, 185-190.
86. Treon, S.P., Shima, Y., Preffer, F.I., Doss, D.S., Ellman, L., Schlossman, R.L., et al. (1999) "TReatment of plasma cell dyscrasias by antibody-mediated immunotherapy", Seminars in Oncology, 26, 97-106.
87. Treon, S.P., Pilarski, L.M., Belch, A.R., Kelliher, A., Preffer, F.I., Shima, Y., et al. (2002) "CD20-directed serotherapy in patients with multiple myeloma: Biologic considerations and therapeutic applications", Journal of Immunotherapy, 25, 72-81.
88. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., et al. (1994) "PHase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma", Blood, 84, 2457-2466.
89. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., et al. (1998) "RItuximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program", Journal of Clinical Oncology, 16, 2825-2833.
90. Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H, Ma, D., et al. (1998) "RItuximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study", Blood, 92, 1927-1932.
91. Teoh, G., Tai, Y.T., Urashima, M., Shirahama, S., Matsuzaki, M., Chauhan, D., et al. (2000) "CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines", Blood, 95, 1039-1046.
92. Urashima, M., Chauhan, D., Uchiyama, H., Freeman, G.J. and Anderson, K.C. (1995) "CD40 ligand triggered interleukin-6 secretion in multiple myeloma", Blood, 85, 1903-1912.
93. Westendorf, J.J., Ahmann, G.J., Armitage, R.J., Spriggs, M.K., Lust, J.A., Greipp, P.R., et al. (1994) "CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line", Journal of Immunology, 152, 117-128.
94. Ocqueteau, M., Orfao, A., Garcia-Sanz, R., Almeida, J., Gonzalez, M. and San Miguel, J.F. (1996) "EXpression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells", British Journal of Haematology, 95, 489-493.
95. Ocqueteau, M., Orfao, A., Almeida, J., Blade, J., Gonzalez, M., Garcia-Sanz, R., et al. (1998) "IMmunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma", American Journal of Pathology, 152, 1655-1665.
96. Lemoli, R.M. and Fortuna, A. (1996) "C-kit ligand (SCF) in human multiple myeloma cells", Leukemia and Lymphoma, 20, 457-464.
97. Furitsu, T., Tsujimura, T., Tono, T., Ikeda, H., Kitayama, H., Koshimizu, U., et al. (1993) "IDentification of mutations in the coding sequence of the proto- oncogene c-kit in a human mast cell leukemia cell line causing ligand- independent activation of c-kit product", Journal of Clinical Investigation, 92, 1736-1744.
98. Pellat-Deceunynck, C., Bataille, R., Robillard, N., Harousseau, JL., Rapp, M.L, Juge-Morineau, N., et al. (1994) "EXpression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells", Blood, 84, 2597-2603.
99. Robillard, N., Jego, G., Pellat-Deceunynck, C., Pineau, D., Puthier, D., Mellerin, M.P., et al. (1998) "CD28, a marker associated with tumoral expansion in multiple myeloma", Clinical Cancer Research, 4, 1521-1526.
100. Shapiro, V.S., Mollenauer, M.N. and Weiss, A. (2001) "ENdogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: Implications for multiple myeloma progression", Blood, 98, 187-193.
101. Guikema, J.E., Hovenga, S., Vellenga, E., Conradie, J.J., Abdulahad, W.H., Bekkema, R., et al. (2003) "CD27 is heterogeneously expressed in multiple myeloma: Low CD27 expression in patients with high-risk disease", British Journal of Haematology, 121, 36-43.
102. Katayama, Y., Sakai, A., Oue, N., Asaoku, H., Otsuki, T., Shiomomura, T., et al. (2003) "A possible role for the loss of CD27-CD70 interaction in myelomagenesis", British Journal of Haematology, 120, 223-234.
103. Zhan, F., Hardin, J., Kordsmeier, B., Bumm, K., Zheng, M., Tian, E., et al. (2002) "GLobal gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells", Blood, 99, 1745-1757.
104. Prasad, K.V., Ao, Z., Yoon, Y., Wu, M.X, Rizk, M., Jacquot, S., et al. (1997) "CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein", Proceedings of the National Academy of Sciences of the United States of America, 94, 6346-6351.
105. Drach, J., Schuster, J., Nowotny, H., Angerler, J., Rosenthal, H., Fiegl, M., et al. (1995) "MUltiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization", Cancer Research, 55, 3854-3859.
106. Flactif, M., Zandecki, M., Lai, J.L., Bernardi, F., Obein, V., Bauters, F., et al. (1995) "INterphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma", Leukemia, 9, 2109-2114.
107. Gutierrez, N.C., Hernandez, J.M., Garcia, J.L., Canizo, M.C., Gonzalez, M., Hernandez, J., et al. (2001) "DIfferences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization", Leukemia, 15, 840-845.
108. Cigudosa, J.C., Rao, P.H., Calasanz, M.J., Odero, M.D., Michaeli, J., Jhanwar, S.C., et al. (1998) "CHaracterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization", Blood, 91, 3007-3010.
109. Zandecki, M., Lai, J.L. and Facon, T. (1996) "MUltiple myeloma: Almost all patients are cytogenetically abnormal", British Journal of Haematology, 94, 217-227.
110. Zojer, N., Konigsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Kromer, E., et al. (2000) "DEletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization", Blood, 95, 1925-1930.
111. Fonseca, R., Harrington, D., Oken, M.M., Dewald, G.W., Bailey, R.J., Van Wier, S.A., et al. (2002) "BIological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: An eastern cooperative oncology group study", Cancer Research, 62, 715-720.
112. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., et al. (2001) "CHromosome 13 abnormalities identified by FISH analysis and serum beta2- microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy", Blood, 97, 1566-1571.
113. Shaughnessy, J., Jr., Tian, E., Sawyer, J., McCoy, J., Tricot, G., Jacobson, J., et al. (2003) "PRognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: Early results of total therapy II", British Journal of Haematology, 120, 44-52.
114. Shaughnessy, J., Tian, E., Sawyer, J., Bumm, K., Landes, R., Badros, A., et al. (2000) "HIgh incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH", Blood, 96, 1505-1511.
115. Elnenaei, M.O., Hamoudi, R.A., Swansbury, J., Gruszka-Westwood, A.M., Brito-Babapulle, V., Matutes, E., et al. (2003) "DElineation of the minimal region of loss at 13q14 in multiple myeloma", Genes Chromosomes Cancer, 36, 99-106.
116. Friend, S.H., Bernards, R., Rogelj, S., Weinberg, R.A., Rapaport, J.M., Albert, D.M., et al. (1986) "A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma", Nature, 323, 643-646.
117. Juge-Morineau, N., Mellerin, M.P., Francois, S., Rapp, M.J., Harousseau, J.L., Amiot, M., et al. (1995) "HIgh incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells", British Journal of Haematology, 91, 664-667.
118. Urashima, M., Ogata, A., Chauhan, D., Vidriales, M.B., Teoh, G., Hoshi, Y., et al. (1996) "INterleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein", Blood, 88, 2219-2227.
119. Avet-Loiseau, H., Li, J.Y., Morineau, N., Facon, T., Brigaudeau, C., Harousseau, J.L., et al. (1999) "MOnosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome", Blood, 94, 2583-2589.
120. Bernasconi, P., Cavigliano, P.M., Boni, M., Astori, C., Calatroni, S., Giardini, I., et al. (2002) "LOng-term follow up with conventional cytogenetics and band 13q14 interphase/metaphase in situ hybridization monitoring in monoclonal gammopathies of undetermined significance", British Journal of Haematology, 118, 545-549.
121. Bergsagel, P.L. and Kuehl, W.M. (2001) "CHromosome translocations in multiple myeloma", Oncogene, 20, 5611-5622.
122. Kuehl, W.M. and Bergsagel, P.L. (2002) "MUltiple myeloma: evolving genetic events and host interactions", Nat. Rev. Cancer, 2, 175-187.
123. Fenton, J.A., Pratt, G., Rawstron, A.C. and Morgan, G.J. (2002) "ISotype class switching and the pathogenesis of multiple myeloma", Hematological Oncology, 20, 75-85.
124. Avet-Loiseau, H., Li, J.Y., Facon, T., Brigaudeau, C., Morineau, N., Maloisel, F., et al. (1998) "HIgh incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies", Cancer Research, 58, 5640-5645.
125. Chesi, M., Nardini, E., Lim, R.S., Smith, K.D., Kuehl, W.M. and Bergsagel, P.L. (1998) "THe t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts", Blood, 92, 3025-3034.
126. Richelda, R., Ronchetti, D., Baldini, L., Cro, L.,Viggiano, L., Marzella, R., et al. (1997) "A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene", Blood, 90, 4062-4070.
127. Shaughnessy, J., Jr., Gabrea, A., Qi, Y., Brents, L., Zhan, F., Tian, E., et al. (2001) "CYclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma", Blood, 98, 217-223.
128. Iida, S., Rao, P.H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., et al. (1997) "DEregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma", Nature Genetics, 17, 226-230.
129. Bergsagel, P.L., Nardini, E., Brents, L., Chesi, M. and Kuehl, W.M. (1997) "IGH translocAtions in multiple myeloma: a nearly universal event that rarely involves c-myc", Current Topics in Microbiology and Immunology, 224, 283-287.
130. Kuehl, W.M., Brents, L.A., Chesi, M., Huppi, K. and Bergsagel, P.L. (1997) "DYsregulation of c-myc in multiple myeloma", Current Topics in Microbiology and Immunology, 224, 277-282.
131. Chesi, M., Bergsagel, P.L., Shonukan, O.O., Martelli, M.L., Brents, L.A., Chen, T., et al. (1998) "FRequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma", Blood, 91, 4457-4463.
132. Hanamura, I., Iida, S., Akano, Y., Hayami, Y., Kato, M., Miura, K., et al. (2001) "ECtopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations", Japanese Journal of Cancer Research, 92, 638-644.
133. Rao, P.H., Cigudosa, J.C., Ning, Y., Calasanz, M.J., Iida, S., Tagawa, S., et al. (1998) "MUlticolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma", Blood, 92, 1743-1748.
134. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.L., et al. (2002) "REcurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy", Blood, 100, 1579-1583.
135. Fonseca, R., Blood, E.A., Oken, M.M., Kyle, R.A., Dewald, G.W., Bailey, R.J., et al. (2002) "MYeloma and the t(11;14)(q13;q32 ; evidence for a biologically defined unique subset of patients", Blood, 99, 3735-3741.
136. Hayman, S.R., Bailey, R.J., Jalal, S.M., Ahmann, G.J., Dispenzieri, A., Gertz, M.A., et al. (2001) "TRanslocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis", Blood, 98, 2266-2268.
137. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., et al. (2000) "DIstinct types of diffuse large B-cell lymphoma identified by gene expression profiling", Nature, 403, 503-511.
138. Tarte, K., De Vos, J., Thykjaer, T., Zhan, F., Fiol, G., Costes, V., et al. (2002) "GEneration of polyclonal plasmablasts from peripheral blood B cells: A normal counterpart of malignant plasmablasts", Blood, 100, 1113-1122.
139. De Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., et al. (2002) "COmparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays", Oncogene, 21, 6848-6857.
140. Zhan, F., Tian, E., Bumm, K., Smith, R., Barlogie, B. and Shaughnessy, J., Jr. (2003) "GEne expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development", Blood, 101, 1128-1140.